ÂÜÀòÂÒÂ×

Wilbur Chan is a corporate finance expert with extensive experience in high-growth biotechnology companies. As Corporate Controller at Nuvation Bio since February 2021, Wilbur has played a key role in transitioning the organization from private to public status, overseeing the implementation of public financial close processes. Prior to this, Wilbur served as Corporate Controller at Curia, leading accounting and financial compliance initiatives following the acquisition of LakePharma, Inc. Wilbur's expertise also includes a significant role at Novartis, where successful management of the IPO-Spin of the Alcon Division involved transforming financial reporting policies. Additional experience includes positions at Pfizer and Penumbra, Inc., as well as a background in assurance services with Ernst & Young. Wilbur holds a degree from the University of California, Berkeley, Haas School of Business.